Specific benefits may be expected with the useof angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptorblockers (ARB) for HT and SGLT2 inhibitors for T2D, as previously addressed, dueto their renoprotective effects [72]. Here, SLC5A2 is linked to type 2 diabetes mellitus.